Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond

@inproceedings{Lscher2016SynapticVG,
  title={Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond},
  author={Wolfgang L{\"o}scher and Michel Gillard and Zara Amanda Sands and Rafal M Kaminski and Henrik V Klitgaard},
  booktitle={CNS drugs},
  year={2016}
}
The synaptic vesicle glycoprotein SV2A belongs to the major facilitator superfamily (MFS) of transporters and is an integral constituent of synaptic vesicle membranes. SV2A has been demonstrated to be involved in vesicle trafficking and exocytosis, processes crucial for neurotransmission. The anti-seizure drug levetiracetam was the first ligand to target SV2A and displays a broad spectrum of anti-seizure activity in various preclinical models. Several lines of preclinical and clinical evidence… CONTINUE READING